Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kura Oncology, Inc. - Common Stock (NQ:KURA)

9.035 -1.165 (-11.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kura Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Kura Oncology Q1 Earnings Call Highlights ↗
Kura Oncology (NASDAQ:KURA) reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad... 
Via MarketBeat
Topics Earnings
Kura Oncology (NASDAQ:KURA) Slips After Q1 Earnings Miss ↗
Via Chartmill
News headline image
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
From Kura Oncology, Inc.
Via GlobeNewswire
News headline image
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
From Kura Oncology, Inc.
Via GlobeNewswire
KURA ONCOLOGY INC (NASDAQ:KURA) Posts Q4 Revenue Beat but EPS Miss, Stock Falls in Pre-Market ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
Uncovering Potential: Kura Oncology's Earnings Preview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
From Kura Oncology, Inc.
Via GlobeNewswire
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Kura Scores A Big Win As FDA Approves Its New Leukemia Pill ↗
Komzifti wins full FDA approval for NPM1-mutated AML, supported by KOMET-001 data, as Wedbush boosts Kura Oncology's price target to $38. 
Via Benzinga
News headline image
Kura Oncology Stock Ignites Retail Frenzy After FDA Clears First Daily Pill For Relapsed Leukemia Patients ↗
The FDA approved KOMZIFTI, a once-daily oral therapy for relapsed or refractory NPM1-mutated AML. 
Via Stocktwits
News headline image
Tech's AI Surge Meets Pharma's Resilient Recovery: A Tale of Two Markets in Late 2025
The financial markets as of November 5, 2025, present a compelling dichotomy with the technology and pharmaceutical sectors charting distinct yet largely positive courses. While technology continues... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Kura Oncology (NASDAQ:KURA) Reports Q3 2025 Revenue Miss But Narrower-Than-Expected Loss ↗
Kura Oncology reported a Q3 2025 revenue miss but a narrower loss. Investors focus on the upcoming FDA decision for its lead drug, ziftomenib, a key catalyst. 
Via Chartmill
News headline image
Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial ↗
Kura Oncology rises after $30M milestone from Kyowa Kirin; Phase 3 ziftomenib dosing and FTI data at ESMO bolster pipeline. 
Via Benzinga
News headline image
Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data
Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant... 
Via MarketMinute
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth ↗
Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential. 
Via Benzinga
News headline image
This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Kura (KURA) Revenue Drops 61% ↗
Via The Motley Fool
News headline image
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe ↗
Via Stocktwits
News headline image
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies ↗
Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA submission set for Q2 2025. 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.